Sepsis is a condition with uncontrolled systemic inflammation, which becomes a life-threatening and overwhelming response to an infection due to the immune system overreacting and damaging blood vessels, resulting in significant damage to tissues and organs.
As an infection transforms into severe uncontrolled systemic inflammation, sepsis progresses to septic shock, the most severe form, diagnosed when blood pressure drops to dangerous levels. The current standard of care in sepsis patients is limited to early treatment with antibiotics and administration of fluids, oxygen and vasopressors (hemodynamic support), followed eventually by corticoid steroids and mechanical ventilation.
Sevuparin, due to its multimodal mechanism of action, has the potential to neutralize and balance harmful processes in this disorder since preclinical data suggests that sevuparin protects the blood vessels during septic inflammatory circumstances by interfering with harmful agents generated by white blood cells 1.
1 Rasmuson et al, 2019
At present, a clinical program for Sevuparin in the treatment of septic shock is being finalized. Modus intends to publish the clinical plan here in the near future.